Ubs Group Ag Immunic, Inc. Call Options Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMUX
# of Institutions
67Shares Held
56MCall Options Held
4.7KPut Options Held
311K-
Bvf Inc San Francisco, CA8.9MShares$10.5 Million0.3% of portfolio
-
Avidity Partners Management LP Dallas, TX8.9MShares$10.5 Million0.49% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.29MShares$8.61 Million0.82% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$8.35 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.59MShares$6.6 Million0.01% of portfolio
About IMMUNIC, INC.
- Ticker IMUX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,565,000
- Market Cap $36.1M
- Description
- Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...